Though the relationship between obesity and hypertension is well established and hypertension has been reported to be the most common comorbidity encountered in patients with cancer, visfatin may be a novel potential therapeutic target for hypertension in cancer patients and survivors. The gene discussed is NAMPT; the disease is obesity disorder.